Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shaughnessy

Showing results (181-190 of 195) with videos related to

Pageof 20
Sort By:
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.
Blood|January 28, 2009
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaDirk Hose, Thierry Rème, Tobias Meissner, et al.
Nature Communications|January 19, 2024
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growthFumou Sun, Yan Cheng, Visanu Wanchai, et al.
Molecular Cancer Therapeutics|September 3, 2009
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee, Susann M Szmania, Myles Dillon, et al.
Haematologica|March 16, 2012
Highly activated and expanded natural killer cells for multiple myeloma immunotherapyTarun K Garg, Susann M Szmania, Junaid A Khan, et al.
Blood|February 6, 2025
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myelomaLi Qin, Luz Yurany Moreno Rueda, Upasana Ray, et al.
Blood|November 16, 2006
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy, Fenghuang Zhan, Bart E Burington, et al.
Cell Reports. Medicine|January 24, 2025
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targetsLuz Yurany Moreno Rueda, Hua Wang, Keiko Akagi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi, Roxanne Steinle, Balaji Balasa, et al.
Cell Reports. Medicine|October 5, 2023
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myelomaYan Cheng, Fumou Sun, Daisy V Alapat, et al.
Pageof 20

Showing results (181-190 of 195) with videos related to

Sort By:
Pageof 20
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.
Blood|January 28, 2009
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaDirk Hose, Thierry Rème, Tobias Meissner, et al.
Nature Communications|January 19, 2024
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growthFumou Sun, Yan Cheng, Visanu Wanchai, et al.
Molecular Cancer Therapeutics|September 3, 2009
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee, Susann M Szmania, Myles Dillon, et al.
Haematologica|March 16, 2012
Highly activated and expanded natural killer cells for multiple myeloma immunotherapyTarun K Garg, Susann M Szmania, Junaid A Khan, et al.
Blood|February 6, 2025
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myelomaLi Qin, Luz Yurany Moreno Rueda, Upasana Ray, et al.
Blood|November 16, 2006
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy, Fenghuang Zhan, Bart E Burington, et al.
Cell Reports. Medicine|January 24, 2025
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targetsLuz Yurany Moreno Rueda, Hua Wang, Keiko Akagi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi, Roxanne Steinle, Balaji Balasa, et al.
Cell Reports. Medicine|October 5, 2023
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myelomaYan Cheng, Fumou Sun, Daisy V Alapat, et al.
Pageof 20